Skip to main content
Erschienen in: Cancer Causes & Control 1/2006

01.02.2006 | Original Paper

Are Findings from Studies of Obesity and Prostate Cancer Really in Conflict?

verfasst von: Stephen J. Freedland, Edward Giovannucci, Elizabeth A. Platz

Erschienen in: Cancer Causes & Control | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Recent studies on the association between obesity and prostate cancer appear to be in conflict. A recent prospective cohort study reported that the incidence of prostate cancer was lower among obese men under the age of 60 years and among those men with a family history of prostate cancer. Similarly, a case–control study found obesity was inversely associated with prostate cancer risk in men aged 40–64 years. However, several prospective cohort studies found that obese men are more likely to die from prostate cancer than non-obese men. Finally, two recent studies found that among men with prostate cancer, obese men were more likely to have a biochemical progression after surgery. We postulate that by closely examining the comparison groups used in these studies, these findings may, in fact, be in agreement. Specifically, this paradox within the literature may result from the possibility that obesity influences the development of aggressive (i.e., higher stage, higher grade, recurrence, death) and non-aggressive disease differently. We suggest that obesity may reduce the risk of non-aggressive disease but simultaneously increase the risk of aggressive disease. Finally, additional methodological issues are discussed that investigators need to be aware of to be able to draw inferences across studies of obesity and prostate cancer outcomes.
Literatur
1.
Zurück zum Zitat Nomura, AM 2001Body size and prostate cancerEpi Rev23126131 Nomura, AM 2001Body size and prostate cancerEpi Rev23126131
2.
Zurück zum Zitat Giovannucci, E, Rimm, EB, Liu, Y, et al. 2003Body mass index and risk of prostate cancer in U.S. health professionalsJ Natl Cancer Inst9512401244PubMed Giovannucci, E, Rimm, EB, Liu, Y,  et al. 2003Body mass index and risk of prostate cancer in U.S. health professionalsJ Natl Cancer Inst9512401244PubMed
3.
4.
Zurück zum Zitat Amling, CL, Riffenburgh, RH, Sun, L, et al. 2004Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomyJ Clin Oncol22439445PubMed Amling, CL, Riffenburgh, RH, Sun, L,  et al. 2004Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomyJ Clin Oncol22439445PubMed
5.
Zurück zum Zitat Freedland, SJ, Aronson, WJ, Kane, CJ, et al. 2004Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study groupJ Clin Oncol22446453PubMed Freedland, SJ, Aronson, WJ, Kane, CJ,  et al. 2004Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study groupJ Clin Oncol22446453PubMed
6.
Zurück zum Zitat Rohrmann, S, Roberts, WW, Walsh, PC, Platz, EA 2003Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancerProstate55140146PubMedCrossRef Rohrmann, S, Roberts, WW, Walsh, PC, Platz, EA 2003Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancerProstate55140146PubMedCrossRef
7.
Zurück zum Zitat Andersson, SO, Wolk, A, Bergstrom, R, et al. 1997Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workersJ Natl Cancer Inst89385389PubMedCrossRef Andersson, SO, Wolk, A, Bergstrom, R,  et al. 1997Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workersJ Natl Cancer Inst89385389PubMedCrossRef
8.
Zurück zum Zitat Rodriguez, C, Patel, AV, Calle, EE, Jacobs, EJ, Chao, A, Thun, MJ 2001Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United StatesCancer Epidemiol Biomarkers Prev10345353PubMed Rodriguez, C, Patel, AV, Calle, EE, Jacobs, EJ, Chao, A, Thun, MJ 2001Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United StatesCancer Epidemiol Biomarkers Prev10345353PubMed
9.
Zurück zum Zitat Calle, EE, Rodriguez, C, Walker-Thurmond, K, Thun, MJ 2003Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adultsN Engl J Med34816251638PubMedCrossRef Calle, EE, Rodriguez, C, Walker-Thurmond, K, Thun, MJ 2003Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adultsN Engl J Med34816251638PubMedCrossRef
10.
Zurück zum Zitat Pasquali, R, Casimirri, F, Cantobelli, S, et al. 1991Effect of obesity and body fat distribution on sex hormones and insulin in menMetabolism40101104PubMedCrossRef Pasquali, R, Casimirri, F, Cantobelli, S,  et al. 1991Effect of obesity and body fat distribution on sex hormones and insulin in menMetabolism40101104PubMedCrossRef
11.
Zurück zum Zitat Slater, S, Oliver, RT 2000Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapyDrugs Aging17431439PubMed Slater, S, Oliver, RT 2000Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapyDrugs Aging17431439PubMed
12.
Zurück zum Zitat Cunha, GR, Hayward, SW, Wang, YZ, Ricke, WA 2003Role of the stromal microenvironment in carcinogenesis of the prostateInt J Cancer107110PubMedCrossRef Cunha, GR, Hayward, SW, Wang, YZ, Ricke, WA 2003Role of the stromal microenvironment in carcinogenesis of the prostateInt J Cancer107110PubMedCrossRef
13.
Zurück zum Zitat D’Amico, AV, Chen, MH, Malkowicz, SB, et al. 2002Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml or lessJ Urol16720252030PubMed D’Amico, AV, Chen, MH, Malkowicz, SB,  et al. 2002Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml or lessJ Urol16720252030PubMed
14.
Zurück zum Zitat Massengill, JC, Sun, L, Moul, JW, et al. 2003Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomyJ Urol16916701675PubMed Massengill, JC, Sun, L, Moul, JW,  et al. 2003Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomyJ Urol16916701675PubMed
15.
Zurück zum Zitat Hoffman, MA, DeWolf, WC, Morgentaler, A 2000Is low serum free testosterone a marker for high grade prostate cancer?J Urol163824827PubMed Hoffman, MA, DeWolf, WC, Morgentaler, A 2000Is low serum free testosterone a marker for high grade prostate cancer?J Urol163824827PubMed
16.
Zurück zum Zitat Schatzl, G, Madersbacher, S, Thurridl, T, et al. 2001High-grade prostate cancer is associated with low serum testosterone levelsProstate475258PubMedCrossRef Schatzl, G, Madersbacher, S, Thurridl, T,  et al. 2001High-grade prostate cancer is associated with low serum testosterone levelsProstate475258PubMedCrossRef
17.
Zurück zum Zitat Platz, EA, Leitzmann, MF, Rifai, N, et al. 2005Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen eraCancer Epidemiol Biomarkers Prev1412621269PubMed Platz, EA, Leitzmann, MF, Rifai, N,  et al. 2005Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen eraCancer Epidemiol Biomarkers Prev1412621269PubMed
18.
Zurück zum Zitat Thompson, IM, Goodman, PJ, Tangen, CM, et al. 2003The influence of finasteride on the development of prostate cancerN Engl J Med349215224PubMedCrossRef Thompson, IM, Goodman, PJ, Tangen, CM,  et al. 2003The influence of finasteride on the development of prostate cancerN Engl J Med349215224PubMedCrossRef
19.
Zurück zum Zitat Talamini, R, Vecchia, C, Decarli, A, Negri, E, Franceschi, S 1986Nutrition, social factors and prostatic cancer in a Northern Italian populationBr J Cancer53817821PubMed Talamini, R, Vecchia, C, Decarli, A, Negri, E, Franceschi, S 1986Nutrition, social factors and prostatic cancer in a Northern Italian populationBr J Cancer53817821PubMed
20.
Zurück zum Zitat Gronberg, H, Damber, L, Damber, JE 1996Total food consumption and body mass index in relation to prostate cancer risk: a case–control study in Sweden with prospectively collected exposure dataJ Urol155969974PubMed Gronberg, H, Damber, L, Damber, JE 1996Total food consumption and body mass index in relation to prostate cancer risk: a case–control study in Sweden with prospectively collected exposure dataJ Urol155969974PubMed
21.
Zurück zum Zitat Freedland , SJ, Terris, MK, Platz, EA, Presti, JC,Jr 2005Body mass index as a predictor of prostate cancer: development versus detection on biopsyUrol66108113PubMedCrossRef Freedland , SJ, Terris, MK, Platz, EA, Presti, JC,Jr 2005Body mass index as a predictor of prostate cancer: development versus detection on biopsyUrol66108113PubMedCrossRef
22.
Zurück zum Zitat Baillargeon, J, Pollock, BH, Kristal, AR, et al. 2005The association of body mass index and prostate-specific antigen in a population-based studyCancer10310921095PubMed Baillargeon, J, Pollock, BH, Kristal, AR,  et al. 2005The association of body mass index and prostate-specific antigen in a population-based studyCancer10310921095PubMed
23.
Zurück zum Zitat Millender, LE, Aubin, M, Pouliot, J, Shinohara, K, Roach, M,3rd 2004Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancerInt J Radiat Oncol Biol Phys59610PubMedCrossRef Millender, LE, Aubin, M, Pouliot, J, Shinohara, K, Roach, M,3rd 2004Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancerInt J Radiat Oncol Biol Phys59610PubMedCrossRef
Metadaten
Titel
Are Findings from Studies of Obesity and Prostate Cancer Really in Conflict?
verfasst von
Stephen J. Freedland
Edward Giovannucci
Elizabeth A. Platz
Publikationsdatum
01.02.2006
Verlag
Kluwer Academic Publishers
Erschienen in
Cancer Causes & Control / Ausgabe 1/2006
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-005-0378-3

Weitere Artikel der Ausgabe 1/2006

Cancer Causes & Control 1/2006 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.